FOR IMMEDIATE RELEASE

P02-51

November 27, 2002

Media Inquiries: 301-827-6242

Consumer Inquiries: 888-INFO-FDA

FDA has approved Claritin (loratadine) as an over-the-counter (OTC) allergy drug product. Previously available only as a prescription drug, Claritin is approved for seasonal allergic rhinitis -- a condition that causes runny nose, nasal congestion, sneezing, and itchy nose, throat, eyes, and ears.


FOR IMMEDIATE RELEASE

CONTACT: Sherrie Borden

301/816-8268; slb@usp.org


/index.php?option=com_iwpfile&file=/dir_01/he2002_2950.pdf

em

The state of California and Los Angeles County Board of Supervisors have filed a new Medicaid waiver application with CMS in a bid to bolster Los Angeles' fiscally troubled health care system. The four-pronged waiver request was submitted Nov. 27. Click here for Press Release On California Waiver


ge

For Release: Immediately

Contact: CMS Press Office, 202-690-6145

HHS TO HELP STATES CREATE HIGH-RISK POOLS TO INCREASE ACCESS TO HEALTH COVERAGE

HHS Secretary Tommy G. Thompson today announced a new program to help states create high-risk pools that will provide health coverage to individuals who otherwise would have difficulty obtaining coverage because of their health status.


/index.php?option=com_iwpfile&file=/dir_01/he2002_2947.pdf

em

FDA Talk Papers are prepared by the Press Office to guide FDA personnel in responding with consistency and accuracy to questions from the public on subjects of current interest. Talk Papers are subject to change as more information becomes available.

T02-48

Media Inquiries: 301-436-2335

November 26, 2002

Consumer Inquiries: 888-INFO-FDA

FDA CLEARS DEVICE TO TREAT FIBROIDS


FDA issued a clarification of its position on the use in animal feed of material from free range deer and elk in areas endemic for Chronic Wasting Disease (CWD) in response to numerous inquiries on the matter. Specifically, FDA says material from CWD-positive animals and untested or CWD-negative animals in CWD endemic areas may not be used as feed ingredients. Click here for FDA Clarification


ce

Keynote address

by

Mark B. McClellan, M.D., Ph.D.

Commissioner of Food and Drugs

for

Health Services and Outcomes

Research Conference

Houston, Texas

November 25, 2002

This text contains Dr. McClellan's prepared remarks. It should be used with the understanding that some material may have been added or deleted during actual delivery.

Good morning, and thank you, Ambassador Djerejian, for your leadership and for the Baker Institute here at Rice University.


/index.php?option=com_iwpfile&file=/dir_01/he2002_2943.pdf

Pages

Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.